Aprea Therapeutics, Inc.
corporate_fare Company Profile
Aprea Therapeutics, Inc. (NASDAQ:APRE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for APRE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 16 rated 8 or above. Recent SEC coverage for APRE spans 8-K, 10-Q, 424B3, S-3.
Recent high-impact activity:
- Aprea Reports Interim Phase 1 APR-1051 Data: Two PRs, 84% Target Engagement
- Aprea Q2 Loss Widens to $0.07/Share as R&D Costs Climb; Cash Runway Extended to Q1 2028
- Aprea Accelerates WEE1 Inhibitor Trial, Plans Q4 Data Readout
- Nasdaq Grants Aprea Therapeutics 180-Day Extension to Regain $1.00 Bid Compliance
- Shareholders Approve Reverse Stock Split to Maintain Nasdaq Listing
Financial Snapshot
Short Interest & Short Volume
2.59 days to coverFINRA reported short interest of 525,159 shares in APRE as of the October 30, 2026 settlement, a 15.4% decrease from the prior period — about 2.6 days to cover at its recent average daily volume. On November 20, 2026, 31.7% of APRE volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.